Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients

Summary

Phase III, multicentre, double-blind, randomised, parallel, equivalence clinical trial to determine the efficacy, safety and immunogenicity of Megalabs® recombinant human alfa epoetin for intravenous use, compared to Epogen®, in the treatment of anaemia in participants with chronic renal disease, dependent on haemodialysis

Timeline

Start

2025-07

Primary completion

2027-03

Completion

2027-03

Drugs

Indications